310 related articles for article (PubMed ID: 36405741)
1. Implications of m6A-associated snRNAs in the prognosis and immunotherapeutic responses of hepatocellular carcinoma.
Zhang C; Zhang W; Shui Y; Li P; Tian Z; Duan S; Wei Q
Front Immunol; 2022; 13():1001506. PubMed ID: 36405741
[TBL] [Abstract][Full Text] [Related]
2. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
3. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
Xiao Y; Li J; Wu J
BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
[TBL] [Abstract][Full Text] [Related]
5. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
6. The m6A/m5C/m1A regulator genes signature reveals the prognosis and is related with immune microenvironment for hepatocellular carcinoma.
Liu T; Sun L; Li ZZ; Yang K; Chen JM; Han XY; Qi LM; Zhou XG; Wang P
BMC Gastroenterol; 2023 May; 23(1):147. PubMed ID: 37170222
[TBL] [Abstract][Full Text] [Related]
7. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
8. Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma.
Deng M; Fang L; Li SH; Zhao RC; Mei J; Zou JW; Wei W; Guo RP
Mutagenesis; 2021 Oct; 36(5):369-379. PubMed ID: 34467992
[TBL] [Abstract][Full Text] [Related]
9. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Jiang H; Ning G; Wang Y; Lv W
Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
[TBL] [Abstract][Full Text] [Related]
10. The significance of m6A RNA methylation regulators in predicting the prognosis and clinical course of HBV-related hepatocellular carcinoma.
Fang Q; Chen H
Mol Med; 2020 Jun; 26(1):60. PubMed ID: 32552682
[TBL] [Abstract][Full Text] [Related]
11. Identification of three m6A-related mRNAs signature and risk score for the prognostication of hepatocellular carcinoma.
Li Z; Li F; Peng Y; Fang J; Zhou J
Cancer Med; 2020 Mar; 9(5):1877-1889. PubMed ID: 31943856
[TBL] [Abstract][Full Text] [Related]
12. An N
Song D; Tian Y; Luo J; Shao G; Zheng J
Ann Transl Med; 2022 Apr; 10(8):464. PubMed ID: 35571429
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma.
Wu X; Zhang X; Tao L; Dai X; Chen P
Biomed Res Int; 2020; 2020():2053902. PubMed ID: 32733931
[TBL] [Abstract][Full Text] [Related]
15. Use of 6 m6A-relevant lncRNA genes as prognostic markers of primary liver hepatocellular carcinoma based on TCGA database.
Zhu XL; Li Q; Shen J; Shan L; Zuo ED; Cheng X
Transl Cancer Res; 2021 Dec; 10(12):5337-5351. PubMed ID: 35116381
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm.
Wang T; Dai L; Shen S; Yang Y; Yang M; Yang X; Qiu Y; Wang W
Front Immunol; 2022; 13():843408. PubMed ID: 35693827
[TBL] [Abstract][Full Text] [Related]
17. Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in hepatocellular carcinoma.
Xie H; Shi M; Liu Y; Cheng C; Song L; Ding Z; Jin H; Cui X; Wang Y; Yao D; Wang P; Yao M; Zhang H
Front Immunol; 2022; 13():914977. PubMed ID: 36032107
[TBL] [Abstract][Full Text] [Related]
18. Analysis of m
Wu X; Wang S; Wu X; Chen Q; Cheng J; Qi Z
J Cancer; 2024; 15(7):2045-2065. PubMed ID: 38434979
[No Abstract] [Full Text] [Related]
19. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
[TBL] [Abstract][Full Text] [Related]
20. Multiple m
Qu N; Qin S; Zhang X; Bo X; Liu Z; Tan C; Wen G; Jiang H
BMC Cancer; 2020 Feb; 20(1):165. PubMed ID: 32111180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
